Market Research Blog

Key Takeaways of Contrast Media Injectors Market Study

• North America is expected to be the most lucrative region and account for more than 32% of revenue in the global contrast media injectors in 2020 and this trend is expected to continue during the forecast period
• Larger patient pool and increasing government support towards developing healthcare system in Asian countries are expected to propel the growth of the contrast media injectors market in the region
• AI is expected to speed up the process of injecting contrast media in the forecast period
• Increasing applications in orthopedic surgeries and neurosurgeries to bolster the market in the forecast period

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-823

Contrast Media Injectors Market Outlook & Key Findings

• Contrast media injectors market likely to grow at over 4.9 % through 2030
• The rising cost of contrast media injectors is expected to hamper the market growth as most small- and medium-sized hospitals cannot afford them
• Extensive research regarding biodegradable contrast media injectors to drive investment in the near future
• Unhealthy lifestyle to propagate the use of contrast media injectors in the upcoming period

Leading Players in Contrast Media Injectors Market

The contrast media injectors market players are trying out every possible mode of organic/inorganic growth to sustain themselves in the market. For instance – Windsong Radiology Group acquired MEDRAD Stellant FLEX Injection System to help both – Windsong and Bayer to avert downtime, standardize care, and minimize operational costs.

Shenzhen Anke High-tech Co. Ltd.’s single-head CT SCAN contrast media injector is endowed with injection interruption that facilitates flexible handling of emergencies. Contrast media injectors offered by Ulrich GmbH & Co. KG facilitate user-friendly handling and have been into the market since the last 3 decades with use in MRI and CT.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-823

The above-mentioned players along with the others in the contrast media injectors market include:

Americas

• Mallinckrodt (Guerbet SA)
• GE Healthcare

Europe

• Bayer AG
• Ulrich GmbH & Co. KG
• Bracco Imaging S.p.A
• Medtron

Asia Pacific

• Nemoto Kyorindo Co. Ltd
• Shenzhen Anke High-tech Co. Ltd

*The list is only for representational purposes not exhaustive. Full competitive intelligence with SWOT analysis available in the report

New Product Launches and Approval – The Ongoing Trend

The market players are into getting their new products launched as well as approved to stay in the competition and also keep pace with the market scenario (that of continuing to innovate). The constructive steps in this regard are:

• In Apr 2020, Guerbet announced getting approved by the US FDA for manufacturing gadoterate meglumine (Dotarem) injection inside the US. Till late 2019, this production used to happen outside of the US.
• In Nov 2019, the US FDA approved an MRI contrast agent “Clariscan” for intravenous use in spine, brain (intracranial), and associated tissues.
• In Aug 2019, Bracco Diagnostics, Inc. announced getting approved by the US FDA for oral suspension of barium sulfate (Varibar Thin Liquid). The basic use of this contrast agent is detection and assessment of dysphagia.

What else is in the report?

Future market insights offer actionable insights and unique perspective on contrast media injectors market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on product type (angiographic injectors, magnetic resonance imaging (MRI) injectors, computed tomography (CT) injectors), by end-user (hospital, ambulatory surgical centres, diagnostics centres) in seven key regions

According to Future Market Insights, the global automated suturing devices is poised to expand at a CAGR of 7.3% to reach a valuation of approx. US$ 473 million through 2021 and beyond.

Increasing research & development for advanced automated suturing devices due to the rising adoption of minimally invasive procedure is anticipated to accelerate the demand across countries such as U.S., Japan, India, China and UK.

Automated Suturing Devices Market Key Highlights from Report

• [257 Pages Report] How will the automated suturing devices market grow in the forecast period of 2021 and 2031?According to FMI, the global automated suturing devices market is poised to expand at over 7.3% CAGR between 2021 and 2031.
• Which is the most lucrative automated suturing devices market?According to FMI, North America is expected to be the most lucrative region over the forecast period of 2021-2031. Within North America, the U.S. is expected to account for maximum sales.
• Who is the leading end user of automated suturing devices?Hospitals are expected to emerge as the leading end user in the automated suturing devices market.
• Which are the prominent automated suturing devices market players?Medtronic Plc., Boston Scientific, C. R. Bard, Inc., Apollo Endosurgery, EndoEvolution, LLC, LSI Solutions, Inc. and SuturTek Inc. are some prominent players operating in the global automated suturing devices market.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-579

Use of automated suturing devices in minimal invasive surgeries, open surgical procedures and major trauma cases that require surgery is expected to drive the market across Asia Pacific excluding Japan (APEJ).

Rising preference for automated suturing devices over conventional ones during laparoscopic surgery is a major factor for market growth. Furthermore, the device is also preferred by procurement teams at hospitals as it’s labelled under “green products”, resulting in considerably less impact on the environment as compared to plastic single-use disposable suturing devices. Thereby, improving the market growth.

Major Key Companies Profiled:

• Medtronic Plc.
• Boston Scientific
• C. R. Bard, Inc.
• Apollo Endosurgery
• EndoEvolution, LLC
• LSI Solutions, Inc.
• SuturTek Inc.

Key Takeaways from FMI’s Automated Suturing Devices Market Study

• By product type, disposable automated suturing devices to emerge as lucrative segment through 2021
• Increasing application in minimally invasive surgeries to stimulate suturing devices sales
• The U.S. is expected to experience noteworthy expansion amid robust presence of regional suture devices manufacturers, experiencing 1.9x growth
• India and China are expected to offer lucrative opportunities across South Asia & East Asia
• Japan is expected to register a stellar growth on the back of rising adoption of minimally invasive procedures
• Growing cases of gastrointestinal diseases to widen automated suturing devices adoption across Germany

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-579

Competitive Landscape

Medtronic Plc., Boston Scientific, C. R. Bard, Inc., Apollo Endosurgery, EndoEvolution, LLC, LSI Solutions, Inc. and SuturTek Inc. are some prominent players operating in the automated suturing devices market.

Product development and innovation of new devices coupled with strategic mergers and acquisition remains the core strategy for the leading players to maintain a strong foothold in the industry.

In December 2019, for instance, a global leading player, Advanced Medical Solutions Group PLC, manufacturer of tissue adhesives, sutures, hemostats, and internal fixation devices, announced the acquisition of Biomatlante, a developer of synthetic bone graft technologies.

In September 2019, another leading player, Apollo Endosurgery, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Polypropylene Suture-Anchor Assembly for the use with the Over Stitch Endoscopic Suturing Systems.

Furthermore, in June 2018, Apollo Endosurgery, Inc. received Special 510(k) clearance from the U.S. Food and Drug Administration for Over Stitch Sx Endoscopic Suturing System. The endoscopic suturing systems allowed physicians to place full-thickness sutures from a flexible endoscope in endoscopic surgery.

As per FMI’s analysis, the market is expected to register double-digit growth, experiencing an impressive CAGR throughout the forecast period. Historically, the market posted credible gains, surpassing US$ 6 billion in 2020, expanding at a CAGR of over 14%. Growth prospects were further heightened during the COVID-19 pandemic, as the scramble for new treatment approaches is prompting pharmaceutical companies to initiate clinical trials for the same.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1107

Prominent pharmaceutical companies are forging long-term partnerships and service agreements with contract research organizations and business processing outsourcing units to enhance existing pharmacovigilance operations by virtue of cost reduction from drug delivery to post-marketing approvals. In April 2021, Thermo Fisher Scientific Inc. announced its plans to acquire Pharmaceutical Product Development (PPD) Inc. for a purchase price of US$ 17.4 billion, which will help enhance the latter’s pharmacovigilance portfolio expansion.

Key Takeaways from FMI’s Pharmacovigilance Market Study

• By phase of drug development, stage IV clinical trials pharmacovigilance solutions account for over 3 out of 4 applications
• Based on method type, targeted spontaneous reporting to make maximum use of pharmacovigilance solutions
• By service provider type, contract outsourcing to generate almost two out of five pharmacovigilance solutions uptake
• US experiencing robust pharmacovigilance solutions providers presence amid prevalence of good PV practices
• Forthcoming clinical trials for numerous drug candidates through 2021 to widen UK’s growth prospects
• India to emerge as an emerging pharmacovigilance hub amid growing trends of medical operations outsourcing
• China to experience growth on the back of recent amendments to render pharmacovigilance implementation stronger

Key Players:

• Accenture Plc.
• Bristol-Myers Squibb
• Clinquest Group B.V.
• Cognizant Technology Solutions
• Covance Inc
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc.
• ICON Plc
• iGATE Corporation
• iMED Global Corporation
• inVentiv Health Inc.
• Novartis AG
• PAREXEL International Corporation
• Pfizer Inc.
• Pharmaceutical Product Development LLC. (PPD)
• PRA Health Sciences Inc.
• Quintiles Transnational Holdings Inc.
• Sanofi SA
• Synowledge LLC
• Wipro Ltd.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1107

Competitive Landscape

Prominent pharmacovigilance solutions providers are relying on collaborating with prominent biopharmaceutical and pharmaceutical companies to offer their digital solutions to facilitate effective patient care solutions. Also, offering advanced solutions is another prominent strategy. Some prominent faces include F. Hoffmann- La Roche, GlaxoSmithKline Plc., Covance Inc., ICON Plc. and iGATE Corporation among others.

Covance Inc. is a prominent pharmacovigilance solutions providing, offering end-to-end PV services spanning clinical and post-marketing phases from medical contract centers to ICSRs to medical reviews to electronic regulatory submissions. The system helps track weekly, daily and monthly metrics for quality, productivity and efficiency.

In April 2020, ICON Plc. initiated efforts to enhance pharmacovigilance practices, considering the onset of COVID-19. A webinar conducted on this issue by the company called for key pharmaceutical companies to automate their workflows by installing proactive and dedicated intelligence processes, forging detailed business and continuity plans and a virtually globally distributed footprint.

Pharmacovigilance Market – Key Segments Covered

Phase of Drug Development

• Preclinical Studies
• Phase I
• Phase II
• Phase III
• Phase IV

Type of Methods

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Service Type Provider

• In-house Pharmacovigilance
• Contract Outsourcing

Geography

• North America (US and Canada)
• Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe)
• Asia-Pacific (China, India, ASEAN, Japan and Rest of APAC)
• Latin America (Brazil, Mexico and Rest of LATAM)
• Middle East & Africa (GCC, South Africa and Rest of MEA)

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1107

According to the report by Future Market Insights, growing incidences of ischemic stroke and diabetes has fueled the demand for hyperbaric oxygen therapy devices across the globe. According to data published by World Health Organization, around 422 Million people suffering from diabetes. Also, 1.6 million people die due to diabetes related diseases states to the study.

Diabetes becomes the breeding ground for various ailments like diabetic foot ulcer, ischemic stroke and chronic infections. Rising cases of diabetes and obesity will fuel the market growth. Hyperbaric oxygen therapy (HBOT) devices deliver 100% pure oxygen to the body tissues at 1.5 to 3 times the normal atmospheric pressure.

Excess oxygen in the blood promotes white blood cells and leucocytes to fight bacteria and promotes the secretion of stem cells for faster healing and restoring normal body function. Introduction of portable hyperbaric oxygen therapy devices and increasing awareness in medical space regarding importance and utility of multiplace HBOT, especially in wound healing will drive the market growth.

In the future, the market is anticipated to grow significantly, as healthcare workers are switching towards hyperbaric oxygen therapy devices for treating soft tissue necrosis. Asia Pacific region is likely to yield highly opportunistic prospects, contributing towards the overall expansion of the market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1099

Key Takeaways from FMI’s Hyperbaric Oxygen Therapy Devices Market Study

• The U.S is expected to dominate hyperbaric oxygen therapy devices market on the back of rising cases of soft tissue necrosis and increasing government funding towards modernization of healthcare infrastructure.
• Rapidly increasing number of people suffering from anemia, especially women under reproductive age will increase hyperbaric oxygen therapy devices adoption across Russia.
• China will offer lucrative opportunities owing to increasing prevalence of osteomyelitis in older population and advancement in healthcare system.
• India is expected to exhibit impressive market growth owing to increase in cancer patients suffering from radiation injury and growing incidence of diabetic foot ulcers in the country.
• Monoplace hyperbaric oxygen therapy devices will continue to encompass maximum market share owing to its low set up time and high availability.

“Rising prevalence of acute and chronic wounds coupled with diabetic foot infection will amplify sales of hyperbaric oxygen therapy devices during the forecast period,” says the FMI analyst.

Competitive LandscapeHyperbaric oxygen therapy devices market is dominated by few global market leaders. Market leaders operating in hyperbaric oxygen therapy devices market are focusing towards employing organic market strategies to consolidate their market position.

Organic strategies include new product development and extensive research and development for product portfolio expansion. They are also working towards launching modern and cheaper medical devices to penetrate the new markets and capture maximum market share especially in emerging economies.

Some market players are employing strategic merger and acquisition and forming an alliance with regional distributors to strengthen their supply chain channels. They are also emphasizing towards faster product approvals, product development and patenting.

Prominent players operating in the hyperbaric oxygen therapy devices market are:-

• ETC BioMedical Systems
• Fink Engineering Pvt. Ltd.
• Gulf Coast Hyperbarics Inc.
• HAUX-LIFE-SUPPORT GmbH
• Hearmec Co. Ltd.
• Hyperbaric SAC
• IHC Hytech B.V.
• OxyHeal Health Group
• Sechrist Industries, Inc.
• SOS Medical Group, Ltd.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1099

More Insights on the Global Hyperbaric Oxygen Therapy Devices MarketIn its latest report, FMI offers an unbiased analysis of the global hyperbaric oxygen therapy devices market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (mono-place HBOT devices, multi-place HBOT devices, and topical HBOT devices) and application (wound healing, decompression sickness, infection, and gas embolism) and North America, Europe, Asia Pacific, and Rest of the World.

Key Segments CoveredBy Product

• Mono-place HBOT Devices
• Multi-place HBOT Devices
• Topical HBOT Devices

By Application

• Wound Healing
• Decompression Sickness
• Infections
• Gas Embolism
• Others

Key Regions Covered

• North America
• Europe
• Asia Pacific
• Rest of the World (ROW)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-1099

Since the past several years, the burden of neurological disorders has increased multifold. According to the National Center for Biotechnology Information (NCBI), the frequency of cerebral aneurysm is nearly 3.2%, with the prevalence being higher amongst women than men above 50 years of age.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-871

It is estimated that around 6.5 million people in the United States possess an unruptured brain aneurysm, while 30,000 suffer a brain aneurysm rupture every year. Based on these trends, it is unsurprising to observe the market being interspersed with the presence of several reputed manufacturers who constantly launch new products.

In addition, rising prevalence of ischemic stroke is also boosting the neurointerventional devices market. Being non-invasive in nature, these devices increase chances of survival during surgery, further fueling market growth. By 2030, a valuation of US$ 4.8 Bn is predicted for the market.

Global Neurointerventional Devices Market- Key Takeaways

• North America shall be the market hegemon, holding a 40.7% market share from 2020-2030
• Embolic coils to capture the majority share, carotid stents to surge in popularity
• High incidence of cerebral aneurysm to accelerate adoption of coiling procedures
• Presence of experienced surgeons shall accelerate hospital-grade neurointerventional device adoption

COVID-19’s Impact on the Market

With respect to neurological disorders, several hospitals and clinics have reported complications in severely or critically ill patients with co-morbidities. COVID-19 has the potential to affect the central and peripheral nervous systems. The virus invades the brain either through the olfactory system or a hematogenous route. Once inside, the virus may cause hypoxic and metabolic abnormalities.

In this light, the neurointerventional devices market is poised to remain afloat in the near-term forecast period. Significant increases in mechanical thrombectomies were reported since April 2020, with majority of the patients seeking treatment for acute strokes from large vessel occlusions (LVOs).

A series of case studies on over 200 COVID-19 positive patients in Wuhan, China, 36.4% of patients exhibited neurologic symptoms such as acute cerebrovascular events, muscle injury and impaired consciousness. In this context, the market is poised to experience an adrenaline rush in the short-run.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-871

Competitive Intelligence

Some influential vendors within the landscape include: Stryker Corporation, Covidien Public Ltd., Penumbra Inc., Terumo Corporation, Johnson & Johnson Private Limited, Medtronic PLC, Boston Scientific Corporation and Abbott.

Players are emphasizing on expanding their businesses through partnerships, collaborations and mergers & acquisitions and participation in trade fairs. Many of them are also aligning with research institutes to augment their research capacities.

In August 2020, Stryker Corporation successfully launched its Surpass Evolve flow diverter after receiving FDA clearance in the U.S market. The device has already been in use in Europe since 2019.

In September 2020, Penumbra Inc. shall participate in the virtual Global Embolization Symposium & Technologies 2020 Conference. The company hopes to broaden its outreach and collaborate with other leading players to develop and launch new neurointerventional devices, thus expanding its existing product portfolio.

Key Segments Covered

Product

• Embolic Coils
• Intracranial Stents
• Carotid Stents
• Thrombectomy Devices
• Intrassacular Devices
• Balloons
• Embolic Protection Devices
• Liquid Embolics
• Stent Retrievers

Technique

• Neurothrombectomy Procedures
• Cerebral Angioplasty
• Stenting
• Coiling Procedures
• Flow Disruption

End User

• Hospitals
• Ambulatory Surgical Centers

Region

• North America
• Latin America
• Europe
• Middle East & Africa (MEA)
• East Asia
• South Asia
• Oceania

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-871

According to the report, increasing focus on pet healthcare is likely to contribute to the build-up of the companion animal drugs market by the end of 2029. Inclination towards compounded drugs to maintain animal health and welfare is expected to increase the sales of companion animal drugs market in 2019 and beyond.

Increasing Urbanization and Growing Affluence in Developing Countries to Benefit the Market

Increasing urbanization level and growing affluence, especially in developing countries, have been driving the adoption of pets, thus leading to increased demand for healthcare products for pets such as companion animal drugs. Continued urbanization has also resulted in increasing prevalence of various diseases such as allergies, lower appetite, reduced energy and behavioral anxieties among small companion animals. This has been driving the demand for innovative classes of medicines such as companion animal drugs.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1077

Upcoming Therapeutic Innovations in Pet Care to Aid Market Growth

Besides traditional drugs, animal health companies have also been investing in smart diagnostic care to help prevent diseases before the actual onset. Companies are also trying to develop generic capabilities to demonstrate bioequivalence to reference prescription drugs in the companion animal drugs market, as many key drugs no longer benefit from intellectual property protection. The development of new vaccines and medications for animals are expected to support the growth of the companion animal drugs market over the forecast period.

Increasing R&D activities and shorter drug-lifecycle are playing an important role in the growth of the companion animal drugs market. Innovations in companion animal drugs are easier and sustainable for a longer period of time, while R&D cycle time are shorter (~ three years) in the Companion Animal Healthcare (CAH) industry as compared to human health, ranging between seven and 15 years for other drugs. This increases return on investment in companion animal drugs and leads to faster profits for the market players.

Collaborative Ventures to Promote the Companion Animal Drugs Market Growth

Collaborative ventures such as One Health promotes unification of veterinary and medical sciences, leading to better disease surveillance, control and education, especially for companion animals such as dogs and cats. One Health venture enables identification of alteration in infection travelling patterns. The patterns are changing mostly in case of parasites due to change in climate and increasing host-vector interactions. Some organizations helping in monitoring of One Health in companion animals are Companion Animal Parasite Council and European Scientific Counsel Companion Animal Parasites.

Such ventures are expected to complement the growth of the companion animal drugs market.

Low Awareness of Animal Diseases to Hamper the Companion Animal Drugs Market Growth

In many developing countries, people lack awareness regarding certain serious companion animal diseases as opposed to livestock diseases, which are more regularly monitored. This is primarily true with regards to pet vaccinations, which is a mandatory requirement for up to three years. Additionally, parasitic medications for companion animals and livestock are different. Lack of awareness with regards to differentiation of these medication varieties leads to adverse drug side effects and thus low administration of companion animal medications. Such factors are likely to create a hindrance in the growth of the companion animal drugs market.

Also, majority of animal healthcare drugs have limited scope for patent extension, primarily due to drug portfolios dominated by drugs that have crossed maturity, which in turn is expected to deter the growth of the companion animal drugs market over the forecast period.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1077

This study underlines key opportunities in the companion animal drugs market and finds that the market would exhibit growth at a value CAGR of ~5% during forecast period. 

Companion Animal Drugs Market: SegmentationProduct Type

• Antibiotics
• Anti-inflammatory
• Parasiticides
• Heart Worm Products
• Behavioral Products
• Nutritional Products
• Skin Care Products
• Vaccines

Distribution channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies and Drug Stores

Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East and Africa

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-1077